Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Y Thomas

Showing results (11-20 of 91) with videos related to

Pageof 10
Sort By:
Biochemical and Biophysical Research Communications|August 29, 2003
Bright stable luminescent yeast using bacterial luciferase as a sensorRose Szittner, Gregor Jansen, David Y Thomas, et al.
Trends in Pharmacological Sciences|February 6, 2013
Novel pharmacological strategies to treat cystic fibrosisJohn W Hanrahan, Heidi M Sampson, David Y Thomas
Current Opinion in Chemical Biology|May 29, 2013
Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosisVéronique Birault, Roberto Solari, John Hanrahan, et al.
Eukaryotic Cell|October 8, 2004
Functional characterization of myosin I tail regions in Candida albicansUrsula Oberholzer, Tatiana L Iouk, David Y Thomas, et al.
Current Opinion in Pharmacology|October 29, 2017
Corrector combination therapies for F508del-CFTRJohn W Hanrahan, Elizabeth Matthes, Graeme Carlile, et al.
Seminars in Cell & Developmental Biology|March 30, 2010
Protein quality control in the ER: the recognition of misfolded proteinsPekka Määttänen, Kalle Gehring, John J M Bergeron, et al.
Gene|January 20, 2005
Drag&Drop cloning in yeastGregor Jansen, Cunle Wu, Babette Schade, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|March 12, 2020
The dual phosphodiesterase 3/4 inhibitor RPL554 stimulates rare class III and IV CFTR mutantsMark J Turner, Yishan Luo, David Y Thomas, et al.
Genes & Development|March 18, 2006
Adaptor protein Ste50p links the Ste11p MEKK to the HOG pathway through plasma membrane associationCunle Wu, Gregor Jansen, Jianchun Zhang, et al.
Pharmacology & Therapeutics|March 4, 2021
Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosisMark J Turner, Kathy Abbott-Banner, David Y Thomas, et al.
Pageof 10

Showing results (11-20 of 91) with videos related to

Sort By:
Pageof 10
Biochemical and Biophysical Research Communications|August 29, 2003
Bright stable luminescent yeast using bacterial luciferase as a sensorRose Szittner, Gregor Jansen, David Y Thomas, et al.
Trends in Pharmacological Sciences|February 6, 2013
Novel pharmacological strategies to treat cystic fibrosisJohn W Hanrahan, Heidi M Sampson, David Y Thomas
Current Opinion in Chemical Biology|May 29, 2013
Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosisVéronique Birault, Roberto Solari, John Hanrahan, et al.
Eukaryotic Cell|October 8, 2004
Functional characterization of myosin I tail regions in Candida albicansUrsula Oberholzer, Tatiana L Iouk, David Y Thomas, et al.
Current Opinion in Pharmacology|October 29, 2017
Corrector combination therapies for F508del-CFTRJohn W Hanrahan, Elizabeth Matthes, Graeme Carlile, et al.
Seminars in Cell & Developmental Biology|March 30, 2010
Protein quality control in the ER: the recognition of misfolded proteinsPekka Määttänen, Kalle Gehring, John J M Bergeron, et al.
Gene|January 20, 2005
Drag&Drop cloning in yeastGregor Jansen, Cunle Wu, Babette Schade, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|March 12, 2020
The dual phosphodiesterase 3/4 inhibitor RPL554 stimulates rare class III and IV CFTR mutantsMark J Turner, Yishan Luo, David Y Thomas, et al.
Genes & Development|March 18, 2006
Adaptor protein Ste50p links the Ste11p MEKK to the HOG pathway through plasma membrane associationCunle Wu, Gregor Jansen, Jianchun Zhang, et al.
Pharmacology & Therapeutics|March 4, 2021
Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosisMark J Turner, Kathy Abbott-Banner, David Y Thomas, et al.
Pageof 10